Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of pCAR-19B in Pediatric Relapsed/Refractory B-ALL
NCT04888468Phase 1Completed
- Sponsor
- Chongqing Precision Biotech
- Start
- Nov 2019
- Primary completion
- Jun 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of priscabtagene autoleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Chongqing Precision Biotech. Primary endpoints: Incidence of Adverse events after pCAR-19B infusion at 28 days and Maximum Tolerated Dose at 28 days. Started Nov 2019; status: completed.
02
Drugs
priscabtagene autoleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04888468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04888468.